Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
A new study is raising eyebrows in both medical and public health circles. Specifically, researchers found that people currently taking GLP-1 receptor agonists appear significantly less likely to engage in violent behavior. This held even when those individuals drank heavily or struggled with impulsive behavior.
The findings come from a 2025 nationally representative U.S. survey of 7,521 adults. Notably, the journal Criminology published this peer-reviewed study. Researchers focused their core analysis on 821 participants who had used a GLP-1 medication at some point. They then compared those still taking the drugs against those who had stopped.
What they found was striking. Impulsivity and alcohol use rank among the strongest predictors of violent behavior. In this study, each standard deviation increase in impulsivity was tied to a 1.9-fold rise in violence. Similarly, heavier alcohol use was tracked with a 1.8-fold increase. Among current GLP-1 users, however, both of those links proved dramatically weaker.
The connection between impulsivity and violence ran roughly 62 percent weaker in current users. Likewise, the link between alcohol use and violence dropped by about 52 percent. In practical terms, therefore, current GLP-1 users who drink or act impulsively are considerably less likely to escalate into violent behavior.
Lead researcher Daniel Semenza, PhD, called the impulsivity finding the study’s most significant result. He serves as director of research at the New Jersey Gun Violence Research Center at Rutgers School of Public Health. Meanwhile, coauthor Christopher Thomas of Rutgers University-Camden offered a compelling interpretation. He suggested the medications may work similarly to cognitive behavioral therapy. Rather than eliminating impulsive thoughts, they may weaken the chain from impulse to action.
That idea has solid biological grounding. Indeed, GLP-1 receptors exist throughout the brain. They concentrate particularly on pathways that govern reward processing and addictive behavior. Furthermore, prior research has already linked GLP-1 drugs to reductions in alcohol consumption and opioid overdose risk. This study, therefore, builds meaningfully on that foundation.
Nevertheless, the researchers remain careful about what the data can and cannot show. This study followed an observational, cross-sectional design. Consequently, it captured a snapshot in time rather than tracking individuals over months or years. That design cannot confirm that the drugs directly cause reduced violent behavior. As a result, reverse causation and unmeasured confounding factors remain real possibilities.
Given this, Semenza and Thomas are calling for longitudinal and experimental research. The current findings thus work best as hypothesis-generating evidence. They do not, consequently, constitute definitive proof of a pharmacological effect on criminal conduct.
From a clinical standpoint, these medications are FDA-approved as prescription-only products. Specifically, semaglutide holds approval as Ozempic for type 2 diabetes and as Wegovy for chronic weight management in adults with obesity. Tirzepatide similarly reaches patients as Mounjaro for type 2 diabetes. Moreover, any expansion of their indications would require separate clinical trials and formal regulatory review.
What makes this research particularly timely is the scale of GLP-1 prescribing across the United States. Indeed, millions of Americans now take these medications daily. Researchers are, therefore, increasingly exploring their broader effects beyond blood sugar and body weight. If future studies confirm behavioral benefits, furthermore, the public health implications would prove far-reaching. They could, consequently, reshape clinical prescribing norms and how policymakers approach violence prevention.
For now, the study adds another important layer to a rapidly evolving picture of what these drugs may do inside the human body and brain.
